Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors

American Heart Journal

Volumn 138, Issue 4 II, 1999, Pages

  Kleiman, N S ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN DERIVATIVE; LAMIFIBAN; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; TIROFIBAN;

BLEEDING; CONFERENCE PAPER; DRUG SAFETY; HEART INFARCTION; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TURBIDIMETRY;

EID: 0032886556     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v138.a100459     Document Type: Conference Paper

References (67)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
2. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286-91.
3. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
4. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
5. Burns ER, Lawrence C. Bleeding time: a guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989;113:1219-24.
6. Bernardi MM, Califf RM, Kleiman N, et al. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. Am J Cardiol 1993;72:1121-5.
7. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol (Lond) 1963;168:178-95.
8. Bell DN, Spain S, Goldsmith HL. Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res 1990;58:47-60.
9. Fujimura K, Phillips DR. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem 1983;258:10247-52.
10. Phillips DR, Charo IF, Parise LV, et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988;71:831-43.
11. Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980;255:154-61.
12. 3-integrins that regulates the dissociation rate for RGD ligands. J Biol Chem 1996;271:21745-51.
13. 3. J Biol Chem 1995;270:9917-25.
14. 3 subunit: cation displacement is involved in ligand binding. Cell 1994;79:659-67.
15. Collen D, Lu HR, Stassen JM, et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GP IIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994;71:95-102.
16. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-94.
17. Rebello SS, Huang JB, Saito K, et al. In vivo efficacy of SM-20302, a GP IIb/IIIa receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterioscler Thromb Vasc Biol 1998;18:954-60.
18. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists. Circulation 1998;98:1616-21.
19. Kuzniar J, Splawinska B, Malinga K, et al. Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition. Int J Clin Pharmacol Ther 1996;34:357-61.
20. DiMinno G, Cerbone AM, Mattioli PL, et al. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985;75:328-38.
21. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-42.
22. Theroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian lamifiban study. Circulation 1996;94:899-905.
23. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
24. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.
25. Vu T-K, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
26. Coughlin SR. Molecular mechanisms of thrombin signaling. Semin Hematol 1994;31:270-7.
27. Bahou WF, Coller BS, Potter CL, et al. The thrombin receptor extra-cellular domain contains sites crucial for peptide ligand-induced activation. J Clin Invest 1993;91:1405-13.
28. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-71.
29. Coller BS, Scudder LE. Inhibition of dog platelet function by in vivo infusion of F(ab′)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985;66:1456-9.
30. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988;77:670-7.
31. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997;96:3860-6.
32. Bachelot C, Rendu F, Gulino D. Anti-GP IIb/IIIa antibodies: powerful tools to investigate function and regulation of an integrin. Semin Thromb Hemost 1995;21:23-36.
33. Mondoro TH, Wall CD, White MM, et al. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor. Blood 1996;88:3824-30.
34. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998;97:5-9.
35. Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985;64:888-96.
36. Greilich PE, Alving BM, O'Neill KL, et al. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Anesth Analg 1997;84:31-8.
37. Alevriadou BR, Moake JL, Turner NA, et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993;81:1263-76.
38. Ross JM, McIntire LV, Moake JL, et al. Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions. Blood 1995;85:1826-35.
39. Strony J, Phillips M, Brands D, et al. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation 1990;81:1106-14.
40. Konstantopoulos K, Kamat SG, Schafer AI, et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995;91:1427-31.
41. Mailhac A, Badimon JJ, Fallon JT, et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: relative contribution of fibrin(ogen) and platelets. Circulation 1994;90:988-96.
42. Turner NA, Moake JL, Kamat SG, et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 1995;91:1354-62.
43. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980;3:135-58.
44. Riess H, Braun G, Brehm G, et al. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol 1986;85:50-6.
45. Sweeney JD, Hoernig LA, Michnik A, et al. Whole blood aggregometry: influence of sample collection and delay in study performance on test results. Am J Clin Pathol 1989;92:676-9.
46. Abbate R, Boddi M, Prisco D, et al. Ability of whole blood aggregometer to detect platelet hyperaggregability. Am J Clin Pathol 1989;91:159-64.
47. Balduini CL, Bertolino G, Noris P, et al. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991;95:82-6.
48. Jordan RE, Wagner CL, Mascelli MA, et al. Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, editor. Adhesion receptors as therapeutic targets. Boca Raton, Fla: CRC Press; 1996. p. 281-305.
49. Faulds D, Sorkin EM. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994;48:583-98.
50. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-8.
51. Simoons ML, de Boer MJ, van den Brand MJ, et al. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
52. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
53. Kleiman NS, Graziadei N, Lance E, et al. Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting [abstract]. J Am Coll Cardiol 1998;31(suppl A):238A.
54. Cattaneo M, Lombardi R, Bettega D, et al. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 1993;13:393-7.
55. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998;128:541-4.
56. Gammie JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998;65:465-9.
57. Juergens CP, Yeung AC, Oesterle SN. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997;80:74-5.
58. Scarborough RM, Rose JW, Hsu MA, et al. Barbourin: a GP IIb-IIIa-specific integrin antagonist from the venom of Sistrurus m barbouri. J Biol Chem 1991;266:9359-62.
59. Scarborough RM, Rose JW, Naughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993;268:1058-65.
60. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80:11B-20B.
61. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
62. Tcheng JE, Thel MC, Jennings L, et al. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose Integrilin in coronary intervention: results of the PRIDE study [abstract]. Eur Heart J 1997;18:624.
63. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
64. Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIA receptor. In: Sasahara AA, Loscalzo J, editors. New therapeutic agents in thrombosis and thrombolysis. New York, NY: Marcel Dekker; 1997. p. 355-65.
65. Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994;56:377-88.
66. Theroux P, White H, David D, et al. A heparin-controlled study of MK-383 in unstable angina [abstract]. Circulation 1994;90:I-231.
67. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-95.